Convergent Therapeutics, Inc.
Eric Sullivan currently serves as the Chief Financial Officer at Convergent Therapeutics, Inc. and holds a position on the Board of Directors as Chair of the Audit & Risk Committee and a member of the Remuneration & Nomination Committee at Chimeric Therapeutics. Previously, Eric Sullivan was the Chief Financial Officer at TCR² Therapeutics Inc. until its acquisition by Adaptimmune in June 2023, and served in various executive finance roles including Chief Financial Officer and Chief Operating Officer at Triplet Therapeutics and Senior Vice President of Finance at Gemini Therapeutics. Eric Sullivan's earlier experience includes senior finance positions at Oncorus, bluebird bio, and Merrimack, along with a background as an Audit Manager at PwC. Education was completed at Bentley University.
This person is not in any teams
Convergent Therapeutics, Inc.
Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.